New Research on Emmaus Life Sciences, Inc. (EMMA-OTCQX)

Posted by Karen Goldfarb

January 24, 2023 at 3:17 PM

An Executive Informational Overview (EIO) is now available on Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies, primarily for rare and orphan diseases, with an initial focus on Sickle Cell Disease (SCD). The 76-page report details the Company's business, its strategy, market opportunities, competition, financials, risks, and more. It is available for download below.

Download Emmaus Life Sciences, Inc. Initiation Report

Read More

Topics: orphan diseases, EMMA, orphan drug, sickle cell crisis, The Steve Harvey Show, emmaus life sciences, sickle cell disease, L-glutamine, endari, diverticulosis

Receive Our Research Notifications

About This Blog

We provide investor-based research and corporate communications services to companies worldwide. Visit our About Us page to learn more.

Posts by Date

see all

Posts by Topic